| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Naoya Kato | |
| Takayuki Kondo | |||
| Masato Nakamura | |||
| Sadahisa Ogasawara | |||
| Makoto Arai | |||
| Akinobu Tawada | |||
| Eiichiro Suzuki | |||
| Yoshihiko Ooka | |||
| Naoya Kanogawa | |||
| Tetsuhiro Chiba | |||
| Tomoko Saito | |||
| Jun Kato | |||
| Shingo Nakamoto | |||
| Kazufumi Kobayashi | |||
| Soichiro Kiyono | |||
| Hiroaki Kanzaki | |||
| Kengo Kanayama | |||
| Susumu Maruta | |||
| Keisuke Koroki | |||
| P2860 | cites work | Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study | Q92343733 |
| Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan | Q92576456 | ||
| Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study | Q92599742 | ||
| Radiation Exposure During Transarterial Chemoembolization: Angio-CT Versus Cone-Beam CT | Q92921118 | ||
| Hepatocellular Carcinoma | Q93002915 | ||
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence | Q93188937 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data | Q31036824 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study | Q33631372 | ||
| Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. | Q33918062 | ||
| Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients | Q34569671 | ||
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. | Q34622672 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study | Q36404761 | ||
| Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma | Q36423170 | ||
| Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome | Q37626587 | ||
| Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization | Q38032905 | ||
| Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update | Q38271759 | ||
| Transarterial chemoembolization: modalities, indication, and patient selection | Q38355409 | ||
| Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. | Q38590448 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy | Q39190041 | ||
| A Randomized Placebo-Controlled Trial of Prophylactic Dexamethasone for Transcatheter Arterial Chemoembolization. | Q40046197 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Q41962614 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? | Q47695578 | ||
| Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization | Q48347936 | ||
| Cone-beam CT acquisition during transradial TACE made easy; use of the swivel arm board | Q49932877 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. | Q50081468 | ||
| Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis | Q50081492 | ||
| Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. | Q51082254 | ||
| Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. | Q51472261 | ||
| Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. | Q51541140 | ||
| Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. | Q52584231 | ||
| Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. | Q54321755 | ||
| Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial | Q56355520 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| Hepatocellular carcinoma | Q58020832 | ||
| Angio-Computed Tomograph-Guided Immediate Lipiodol Computed Tomograph for Diagnosis of Small Hepatocellular Carcinoma Lesions during Transarterial Chemoembolization | Q58585127 | ||
| Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases | Q59150373 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma | Q64060066 | ||
| 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma | Q64272871 | ||
| Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC) | Q83157920 | ||
| EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | Q88301343 | ||
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 | ||
| Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma | Q90318939 | ||
| Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update | Q92125346 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 2 | |
| P921 | main subject | systemic therapy | Q1929812 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 155-162 | |
| P577 | publication date | 2020-01-15 | |
| 2020-04-01 | |||
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Switching to systemic therapy after locoregional treatment failure: Definition and best timing | |
| P478 | volume | 26 |
| Q97645885 | Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection | cites work | P2860 |
Search more.